Siltuximab for Preventing Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge
Phase 2
40
about 6.5 years
18+
1 site in OH
About this study
This trial is testing if giving siltuximab during the reintroduction of immune checkpoint inhibitor (ICI) therapy can prevent severe immune-related adverse events (irAEs) in patients with advanced cancer. ICI therapy may cause severe irAEs that can affect many organs, potentially leading to stopping treatment early and progression. Siltuximab is a monoclonal antibody that may help reduce inflammation and prevent these severe irAEs during the rechallenge.
Based on ClinicalTrials.gov records.
What participants do
- 1.Quality-of-Life Assessment
- 2.Receive Anti-PD-L1 Monoclonal Antibody
- 3.Receive Anti-PD1 Monoclonal Antibody
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
siltuximab
injection (Injection)
Primary: Incidence of severe immune-related adverse event (irAE)
Secondary: Median progression-free survival, Overall response rate, Overall survival
biopsy, diagnostic, imaging